Collaborative Molecular Epidemiology Study of Metabolic Dysregulation, DNA Methylation, and Breast Cancer Risk Among Nigerian Women: MEND Study Objectives and Design by Akinyemiju, Tomi et al.
original
report
Collaborative Molecular Epidemiology Study of
Metabolic Dysregulation, DNA Methylation, and
Breast Cancer Risk Among Nigerian Women:
MEND Study Objectives and Design
Tomi Akinyemiju, PhD,MS1; Omolola Salako, MBBS2; Adetola Daramola, MBBS2; Olusegun Alatise, MD,MSc3; Adewale Adeniyi, MBBS4;
Gabriel Ogun, MD5; Omobolaji Ayandipo, MD5; Thomas Olajide, BM, BCh2; Olalekan Olasehinde, MD, MS3; Olukayode Arowolo, MD3;
Adewale Adisa, MD3; Oludolapo Afuwape, MBBS5; Aralola Olusanya, MBChB5; Aderemi Adegoke, MBBS6; Akinlolu Ojo, MD7;
Trygve Tollefsbol, PhD, DO8; and Donna Arnett, PhD1
abstract
PURPOSE To elucidate the role of metabolic dysregulation and associated DNA methylation changes on breast
cancer risk and aggressive subtypes among Nigerian women. We describe the design and methods of
a collaborative molecular epidemiology study of breast cancer in Nigerian hospitals.
METHODS The Mechanisms for Novel and Established Risk Factors for Breast Cancer in Women of Nigerian
Descent (MEND) study was designed as a matched case-control study of 350 patients, age 18 to 75 years, with
newly diagnosed, treatment-naı¨ve breast cancer and 350 age-matched healthy controls from surrounding
geographic areas. Patients with breast cancer seen for initial diagnosis at four large tertiary hospitals in southwest
Nigeria and one afﬁliated private hospital were recruited. Healthy female controls were selected from a cohort of
4,000 healthy women recruited as part of the HumanHeredity and Health (H3) in Africa Chronic Kidney Disease
Case-Control Study in Nigeria. Tumor and adjacent normal tissue, and blood and saliva samples were collected
for molecular and epigenetic assays.
RESULTS Although recruitment is ongoing, a total of 416 patients have been recruited to date, with tumor and
blood samples obtained from at least 310 patients. Data on age-matched (6 6 months) controls have also been
obtained and harmonized. Lipid assays for 350 pathologically veriﬁed cases and 350 age-matched controls is
underway, and pathologic characterization of tumors (including immunohistochemistry for subtyping) is on-
going. Data on DNA methylation for tumors and adjacent normal tissue are expected by the end of the study
period.
CONCLUSION The MEND study will provide a unique, high-quality source of data to evaluate the contribution of
metabolic dysregulation such as obesity, diabetes, hypertension, and metabolic syndrome to the biology of
breast cancer among Nigerian women and foster collaborative studies relevant for women of African descent
globally.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Developing countries accounted for 45% of new
breast cancer cases globally in 2009 and 57% in
2012, with these proportions projected to increase
to 70% by 2030.1,2 This dramatic increase is con-
sistent with the epidemiologic transition, a stage in
a country’s economic development characterized by
declines in infectious diseases and increases in
noncommunicable diseases as the leading causes of
death, coinciding with an increase in the proportion
of people living above the poverty level.3 Nigeria,
accounting for one-sixth of the entire African pop-
ulation, is classiﬁed by the World Bank as a lower-
middle income country with a rapidly growing
economy4 and is swiftly undergoing an epidemiologic
transition. This is evidenced by an increase in the
prevalence of so-called diseases of afﬂuence that
result in higher rates of metabolic dysregulation,
characterized by obesity, hypertension, diabetes, and
metabolic syndrome (MetS).5 These cardiometabolic
risk factors are associated with substantially increased
risk of coronary heart disease, stroke, and type-2
diabetes,6-11 and prevalence of MetS is estimated to
be 35% to 43% in urban areas of Nigeria.12,13 Given
a consistent association with increased risk of breast
cancer in other settings,14,15 the coinciding epidemics
of MetS and breast cancer in Nigeria are cause for
concern.
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In Nigeria, breast cancer incidence increased three-fold
from 15 cases per 100,000 in 1973 to 52 cases per
100,000 in 2012.16,17 Breast cancer in Nigeria also exhibits
several epidemiologic features that are striking when
compared with the disease in developed countries. First,
the majority of cases are premenopausal, with more than
70% of patients diagnosed between ages 20 and
50 years16,18; this is similar to patterns observed among
women of African descent in the United States and the
United Kingdom but in contrast with predominantly post-
menopausal breast cancer observed among white
women.19-21 Many established risk factors for breast can-
cer, such as low parity and lack of breastfeeding, are less
common in Nigerian women and typically are associated
with postmenopausal breast cancer22-24; however, risk
factors for premenopausal breast cancer are not well un-
derstood. Second, 60% to 80% of patients with breast
cancer in Nigeria are diagnosed at stages III or IV with high-
grade disease,25-28 because of a combination of infrequent
screening and fast-growing tumors. Comparably aggressive
phenotypes have also been documented among women of
African descent in the United States and the United
Kingdom, where better screening strategies exist, whereas
less aggressive phenotypes are observed in white
women.27,29-31 Third, several studies have reported that,
similar to women of African descent in the United States
and United Kingdom, but in contrast with white women,
breast tumors in Nigerian women are more likely to be
receptor negative for estrogen, progesterone, and human
epidermal growth factor 2 (ie, triple-negative breast
cancer).28,32 Fourth, differential DNA methylation of genes
involved in tumor suppression and DNA repair has been
implicated in young onset, aggressive, triple-negative
breast cancer subtypes among black women versus with
white women,33 although this pattern has not been well
characterized in Nigerian women.
Despite the striking similarities in breast cancer pheno-
types among Nigerian women and other women of African
descent and in contrast with white women, molecular
epidemiology studies characterizing the biologic mecha-
nisms associated with the aggressive subtypes frequently
observed among women of African descent remain scarce.
Metabolic dysregulation may inﬂuence breast cancer eti-
ology, aggressiveness, and outcomes via pathways that
involve (1) higher circulating insulin levels leading to mito-
genic, antiapoptotic, and angiogenic properties; (2) chronic
inﬂammation; and (3) increased visceral fat stores and
other cancer-associated adipokines that may promote tu-
mor growth.34 However, no study, to our knowledge, has
evaluated whether DNA methylation, given its sensitivity to
environmental and genetic cues, may provide additional
insights into unique biologic mechanisms through which
metabolic dysregulation or MetS increases risk of breast
cancer and aggressive subtypes in Nigerian women (Fig 1).
We hypothesize that MetS may induce differential methylation
in key breast cancer–related genes, leading to increased
breast cancer risk. We previously reported an association
between MetS and differential DNA methylation in the
ABCG1 gene involved in cellular cholesterol transport and
found to be altered in approximately 35% of breast cancer
cases.35 The current study will provide critical epidemiologic
and clinical data on a wide range of novel and established
breast cancer risk factors that can serve as a basis for future
investigations into determinants of breast cancer risk and
survival among African women in Nigeria. Here, we describe
the design and methods of the Mechanisms for Novel and
Established Risk Factors for Breast Cancer in Women of
Nigerian Descent (MEND) study.
Objectives of MEND
The MEND study was designed to generate high-quality
epidemiologic, molecular, and epigenetic data regarding
the role of metabolic dysregulation in breast cancer risk and
subtypes in Nigeria. The primary aims are as follows:
1. To recruit 350 patients (18 to 75 years of age) with
newly diagnosed, treatment-naı¨ve breast cancer from
tertiary hospitals in Nigeria, and 350 age-matched
healthy controls;
2. To determine the prevalence of metabolic dysregu-
lation (ie, obesity, diabetes, high blood pressure,
dyslipidemia, elevated triglyceride levels, and MetS)
among cases and controls, and estimate the asso-
ciation between MetS and components with breast
cancer subtype; and
3. To characterize genome-wide DNAmethylation levels
in tumor and adjacent normal tissue from incident
breast cancer cases and identify differentially meth-
ylated genes by MetS status.
METHODS
Study Design and Organization:
The study was originally designed as a matched case-
control study of 350 patients, 18 to 75 years of age, with
newly diagnosed, treatment-naı¨ve incident breast cancer,
Environment and lifestyle
factors (eg, obesity)
Metabolic
syndrome
DNA methylation
Breast
cancer
Genetic background
FIG 1. Conceptual framework of metabolic syndrome and breast
cancer. Adapted from Hauner et al.14
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and 350 age-matched healthy controls from surrounding
geographic areas (Appendix; Appendix Table A1). The or-
ganization of MEND comprises a team of collaborators from
four tertiary hospitals and one private hospital in southwest
Nigeria: Lagos University Teaching Hospital, Idi-Araba,
Lagos State; Federal Medical Center, Idi-Aba, Abeokuta,
Ogun State; University College Hospital, Ibadan, Oyo State;
Our Lady of Apostle Catholic Hospital, Ibadan, Oyo State; and
Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun
State. The hospital sites were selected on the basis of location
in densely populated regions of the country to enhance
a rapid pace of recruitment; reputable tertiary hospitals with
established breast cancer clinics; collaborative opportunity
with breast cancer specialists to facilitate administrative
approvals and patient recruitment; and proximity to com-
mercial or urban city centers to facilitate transfer of supplies
to and from Nigeria. Research teams at each site included at
minimum a pathologist, oncologist (medical, radiologic, and/
or surgical), research nurse, and laboratory technician. Study
methods were reviewed and approved by collaborators and
institutional review boards at each research site, as well as
the institutional review boards at the University of Alabama at
Birmingham and the University of Kentucky.
Recruitment and Baseline Assessment
Recruitment of cases and collection of baseline data
continues and were designed to occur primarily during the
initial diagnostic visit, on the basis of a probable breast
cancer diagnosis by an oncologist but before pathologic
conﬁrmation. This approach ensured that data, physical
measurements, and samples were obtained before treat-
ment, and reduced the impact of patient loss to follow-up,
a common occurrence in this setting.
Breast Cancer Cases
Figure 2 illustrates the study procedure. After a patient
received an initial, probable diagnosis of breast cancer, the
research study was brieﬂy explained to the patient and if
the patient expressed interest, the research nurse fully
explained the study requirements in an adjoining exami-
nation room. Patients were free to refuse to participate at
any point during the study. Eligibility was determined on the
basis of a series of initial questions, and exclusion criteria
included previous diagnosis and/or treatment of cancer,
medical conditions that could prevent long-term partici-
pation, cognitive impairment judged by the research nurse,
or inability to communicate in English without a family
member who could translate. The research nurse then
completed the informed consent procedure and obtained
verbal and written informed consent. Because English is
the ofﬁcial language of Nigeria, most patients understood
and spoke at least some English or were accompanied by
family members who could translate. After informed con-
sent was given, extensive demographic and epidemiologic
Informed Consent
Questionnaire
Demographics: Age, ethnicity
Reproductive: Parity, menarche, menopause
Risk factors: Smoking, alcohol, diet, PA
Mental health: Anxiety, depression
Biomarkers
Height
Weight
Hip
Blood pressure
Blood
Buffy coat
Serum
Red blood cells
Saliva 
Oragene
Biopsy 
Tumor - Paxgene (–80ºF)
Tumor - Cryovial (–80ºF)
Adjacent Normal - Paxgene
Medical Record Review
Disease - Stage, grade, laterality, size
Treatment - Chemotherapy, radiation, surgery (time, dose, duration)
Pathology – Tubule, nuclei, mitosis, grade, HER2, hormone receptor status (ER, PR, AR)
Follow-up interview – Vital status, treatment status, recurrence, treatment adverse effects
1 year follow-up
S
A
M
P
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FIG 2. Schema of the mechanisms for novel and established risk factors for breast cancer in women of Nigerian
descent study design. AR, androgen receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor
2; Oragene, Oragene Saliva Collection Kit; PA, physical activity; PR, progesterone receptor.
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data were obtained via a standardized interview conducted
on the Qualtrics application (Qualtrics, Provo, UT) for iPad.
The Qualtrics survey application provided a high level of
quality control and standardization across sites and in-
terviewers, and the ofﬂine mode ensured that data were
captured and stored securely even when Internet access
was inconsistent. The questionnaire interview lasted an
average of 45 minutes. To calibrate blood glucose mea-
sures, patients were asked about time since their last meal,
because it was not feasible to inform patients to fast
overnight before recruitment.
Next, the research nurse obtained physical measurements,
including height (Seca 217 Portable Stable Stadiometer;
Seca, Hamburg, Germany), weight (Seca Flat Scale Model
876), waist circumference (Lufkin W606 PM measuring
tape), and blood pressure (average of two measurements;
Omron HEM-907XL; Omron, Kyoto, Japan) using equip-
ment standardized across all study sites. In addition, two 8-
mL venous blood samples were obtained (BD Vacutainer
Safety-Lok blood collection set; BD, Franklin Lakes, NJ),
and stored in purple top (BD K2 EDTA; Thermo Fisher
Scientiﬁc, Waltham, MA) and plain vacutainer blood col-
lection tubes, and saliva samples were stored directly in an
Oragene Saliva Collection Kit (ORG 500; DNA Genotek,
Ottawa, Canada). After data and sample collection,
a routine biopsy was performed. Sterile tissue containers
(PAXgene Dual Chamber Tissue Container and 2-mL
cryovial; QIAGEN, Hilden, Germany), a biopsy needle
(Temno T149 14G Semi-Automatic Biopsy needle, Merit
Medical, South Jordan, UT), and ancillary materials (eg,
surgical gloves, methylated spirit, bandages, and lidocaine)
were provided by the study for routine pathologic evalua-
tion, as well as tumor and adjacent normal tissue collection
(from the affected breast) for research purposes. Finally,
the patient was provided with an incentive of a N500
(equivalent to approximately US$ 1.50) telephone recharge
card for their participation, and the biopsy needle (N14,000
locally; approximately US$ 53) was provided by the study
for free (patients are normally required to purchase the
needle and other ancillary items needed for the biopsy from
personal funds). The research samples were immediately
(within 30 minutes) delivered to the laboratory technician
for processing and storage in −80°C freezers. Routine
treatment and follow-up continued for patients as usual.
Sample Handling and Shipment
Biologic specimens were labeled with unique patient
identifying numbers (PIDs), data of collection and sample
type, and then stored in −80°C freezers in institutional
laboratories. Laboratory freezers are powered year-round
using a combination of national electricity supply, back-up
power generators, and inverters. Every 3 to 4 months,
samples were packaged in freezer boxes, arranged in dry
shippers charged with liquid nitrogen (a method validated
to remain at approximately −150°F for up to 14 days), and
shipped to the United States. Liquid nitrogen was available
for purchase in Lagos (BOC Gases, Lagos), and dry ship-
pers were initially charged, transported back to the labo-
ratory to be stocked and recharged, and then picked up by
a World Courier representative (World Courier Inc). The dry
shipper with samples was delivered to the Pathology
Shared Resource Facility at the University of Kentucky
Markey Cancer Center within 5 to 7 days, and samples were
immediately transferred into −80°C freezers.
Data Handling, Management, and Processing
Research nurses at each institution maintained a patient-
tracking database that was continuously updated with in-
formation on date of recruitment, sample or data collected
(ie, interview, blood, tumor, normal, saliva), incentive re-
ceived, contact information, next of kin, and notes on re-
cruitment process. De-identiﬁed recruitment and clinical
data from each site, labeled with a unique PID, were sent to
theMEND data manager in the United States for integration
into a single data management system. Survey data from
Qualtrics were downloaded and checked for completeness
and consistency. A US pathologist reviewed each tissue
sample for pathologic veriﬁcation of tumor status and im-
munohistochemistry (IHC) staining for receptors of estro-
gen, progesterone, human epidermal growth receptor 2,
androgen, and Ki-67 was performed. Blood samples were
analyzed at a clinical research laboratory to assess for
cholesterol, triglyceride, and blood glucose levels. In ad-
dition, pathologically veriﬁed tumor and adjacent normal
samples were sent to a genomics laboratory for epigenome-
wide DNAmethylation analysis. Survey and clinical data, as
well as results from the pathology, biomarker, and meth-
ylation assays, were cleaned and integrated into the ﬁnal
study analytical data set. The MEND data manger con-
ducted detailed quality checks on all data items and
requested clariﬁcation from local interviewers and research
coordinators for missing or inconsistent variables when
needed. All corrections were carefully annotated and in-
tegrated into the main study database for additional
analysis. Each institution received a data set with data on
patients recruited at their institutions only identiﬁed with the
PID (to be decoded by site research nurses) as well as
laboratory results from US pathology, IHC, and clinical
assays for comparative purposes.
Personnel Training and Quality Control
Research nurses were carefully selected by site collab-
orators and trained extensively to ensure that study pro-
tocols were followed closely, errors in data collection were
minimized, and biologic samples were handled safely and
properly to ensure quality. Research nurses were trained
to emphasize the importance of patient privacy and
conﬁdentiality, and were monitored for sensitivity to pa-
tients who were receiving a new cancer diagnosis—a
devastating experience in any environment, but especially
in Nigeria, where cancer stigma still exists. Research
nurses completed human subjects’ protection and
Akinyemiju et al
4 © 2019 by American Society of Clinical Oncology
Downloaded from ascopubs.org by The University of Arizona on August 5, 2019 from 150.135.118.049
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
extensive patient-interview training before working on the
project.
Healthy Controls
Rather than recruit controls de novo as previously de-
scribed, healthy controls were selected from a cohort of
4,000 women recruited as part of the Human Heredity and
Health (H3) Africa Chronic Kidney Disease (CKD) Case-
Control Study in Nigeria, predominantly from Lagos, Ogun,
Oyo, and Osun states (the same geographic region as the
MEND study), and age matched (6 6 months) with breast
cancer cases at enrollment. Sample and data collection
protocols were similar between the CKD and MEND
studies. Speciﬁcally, each breast cancer case was matched
on age with one healthy control woman without re-
placement, so that once a control was matched, she was
ineligible for matching with other cases. A nearest-
matching approach was used such that if there was no
control with age 6 6 months of the case, then the control
closest in age was chosen. This approach has been used
routinely in matched case-control studies.36-38 Important
study covariates such as sociodemographics, physical
measurements, reproductive factors, and family and per-
sonal health for the CKD controls were obtained, as well as
1 mL of serum for biomarker analysis of MetS components.
Participant Follow-Up
Active and passive surveillance of recruited patients was
conducted to ascertain fatal and nonfatal cancer outcomes.
Patients were contacted by telephone every 12 months
around the time of their recruitment anniversary, and ad-
ditional data were collected on vital status, self-reported
physician diagnosis of recurrence, metastasis or remission,
adverse effects of treatment, and quality of life. If the patient
was unable to respond to follow-up calls or the patient could
not be reached, the next of kin was contacted to complete
the interview. Working closely with institutional collabora-
tors, research nurses requested access to patient medical
records 6 to 12 months after diagnosis and recruitment,
and resident doctors assisted with abstracting relevant
information on pathology, surgery, chemotherapy, radia-
tion, recurrence, or metastasis.
RESULTS
Current Status
A total of 416 patients with breast cancer have been
recruited to date (Table 1), 372 of whom have provided
blood samples, and 310 also with tumor tissue sample.
Approximately 15% of probable breast cancer cases were
benign, based on initial pathologic evaluation by Nigerian
pathologists. Overall, 15 patients were approached about
participation but refused, and one patient initially agreed to
participate but eventually withdrew from the study.
As expected, there was no statistically signiﬁcant difference
in age between cases and controls, as a result of matching
(Table 2). However, cases compared with controls were
slightly older, on average, at menarche (15.43 v 15.37
years) and menopause (48.15 v 47.88 years), had higher
diastolic blood pressure (80.17 v 79.13 mm Hg), were less
likely to self-report a history of hypertension (17.54% v
45.79%) or diabetes (2% v 19%), and had slightly fewer
pregnancies (4.36 v 4.77).
DISCUSSION
The MEND study will generate and integrate patient data at
the epigenetic (tissue, blood, and/or saliva samples), mo-
lecular (blood and tissue samples), pathologic (IHC and
tumor makers), individual (questionnaire data), and clinical
(treatment, follow-up) levels to improve understanding of
the unique features of breast cancer in Nigeria and to
assess the contribution of metabolic dysregulation on
breast cancer outcomes. The ﬁrst MEND scientiﬁc papers
will focus on the topics highlighted in the introduction—the
role of obesity, diabetes, and MetS, and the epigenetic
mechanisms linking these exposures with breast cancer
incidence and subtypes. We will explore these topics fur-
ther by examining other novel risk factors for breast cancer
in this setting, including metabolic and inﬂammatory bio-
markers, changes in body size over the life course, social
determinants, and other genomic markers, and we will re-
examine the role of established risk factors for breast
cancer subtypes in this setting (eg, reproductive risk fac-
tors, diet, physical activity).
The study design for MEND is motivated primarily by the
desire to improve understanding and meaningfully affect
the prevention and treatment of breast cancer in Nigeria.
Although there are several inherent limitations to the
TABLE 1. MEND Recruitment Progress Report as of September
10, 2018
Recruitment Step
No. of Cases
LUTH FMC UCH OUATHC Total
Interview 108 59 75 177 419
Blood 92 45 59 177 374
Tumor: PAXgene* 97 19 77 120 314
Tumor: Cryovial† 22 8 0 164 194
Normal: PAXgene 49 16 74 116 255
Normal: Cryovial 9 8 0 147 164
Saliva 58 21 51 83 213
Withdrawal‡ 0 1 0 0 1
Refusal§ 5 2 7 1 15
Abbreviations: FMC, Federal Medical Center; LUTH, Lagos
University Teaching Hospital; OUATHC, Obafemi Awolowo University
Teaching Hospital; UCH, University College Hospital.
*Tissues were ﬁxed using the PAXgene tissue-ﬁx container.
†Tissues were fresh frozen.
‡Consented to participate but withdrew before the completion of
research.
§Approached but refused to participate.
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case-control study design, such as the potential for dif-
ferential misclassiﬁcation of exposures, recall bias, and
limitations to external generalizability, this design was the
most efﬁcient for the study setting and can serve as a basis
for larger prospective studies that may address these
limitations.
There are many important scientiﬁc questions relevant to
improving health and reducing fatal and nonfatal disease
outcomes in lower- and middle-income countries, which
require better understanding of etiology and biologic
mechanisms involved. This information may also enhance
treatment strategies in high-income countries. However,
there are signiﬁcant challenges associated with developing
high-quality molecular epidemiology studies in resource-
limited settings. These may include logistical challenges,
difﬁculty identifying and cultivating scientiﬁc collabora-
tions, cultural and language barriers, cost, time frame, and
administrative hurdles. Important scientiﬁc questions are
likely to remain unanswered if these challenges or barriers
are not addressed, and, as the MEND study shows, the
challenges are surmountable.
Studies using the extensive MEND data and infrastructure
will focus on characterizing other genomic features of
Nigerian patients with breast cancer and incorporate
a prospective assessment of survival. MEND data will foster
collaborative studies to better understand breast cancer
risk patterns among Africans (Nigerian) and women of the
African diaspora, including women of African descent in
the United States, United Kingdom, and the Caribbean.
Given their shared genetic ancestry, these studies may help
elucidate key genetic risk factors that may be conserved
across generations, and the impact of distinct environ-
mental and/or lifestyle conditions on breast cancer risk.
Findings from these studies can enhance the genetic di-
versity of pooled studies, provide empirical data that can be
used to tailor breast cancer prevention strategies to speciﬁc
risk factors relevant for different racial groups, and reduce
the burden of breast cancer globally.
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TABLE 2. Baseline Characteristics of Mechanisms for Novel and Established Risk Factors for Breast Cancer in Women of Nigerian Descent Study
Cases and Controls
Characteristic Cases Controls P
Age, mean (SD), years 48.62 (11.60) 48.48 (11.43) .337
Age at menarche, mean (SD), years 15.43 (3.85) 15.37 (2.20) , .001
Age at menopause, mean (SD), years 48.15 (5.66) 47.88 (5.34) , .001
BMI, mean (SD), kg/m2 26.54 (8.05) 26.83 (5.91) .152
DBP, mean (SD), mm Hg 80.17 (18.33) 79.13 (14.77) .0002
SBP, mean (SD), mm Hg 129.27 (21.96) 132.28 (29.14) .404
Waist circumference, cm 93.13 (19.08) 90.98 (14.86) .340
History of HPN, No. (%) 67 (17.54) 163 (45.79) , .001
History of diabetes, No. (%) 8 (2.09) 56 (19.05) , .001
Hormonal birth control, mean (SD), years 5.22 (4.60) 7.59 (13.70) .318
No. of pregnancies, mean (SD) 4.36 (1.96) 4.77 (2.36) .021
Live births, mean (SD) 3.67 (1.85) 3.83 (2.71) .540
Menopausal status, No. (%)
Postmenopausal 177 (46.34) 78 (21.60) , .001
Premenopausal 185 (48.43) 283 (78.40)
Perimenopausal 20 (5.24)
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure.
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APPENDIX
Analytical Approach
Descriptive statistics for baseline sociodemographic, clinical factors
and metabolic syndrome (MetS) components will be conducted to
assess for signiﬁcant differences between cases and controls. Given
the matched study design, conditional logistic regression analysis will
be used to examine the association between the main exposure
variable and the outcome of interest (eg, MetS and breast cancer
hormone receptor subtype). All statistical models will be adjusted for
potential confounding by age, marital status, socioeconomic status,
family history of cancer, and reproductive history. P = .05 will be
considered statistically signiﬁcant and for interaction terms, P ≤ .1 will
be considered signiﬁcant. All epidemiologic analyses will be con-
ducted using SAS (SAS Institute, Cary, NC). For methylation data, we
will ﬁt linear mixed-effect regression models with the CpG β score
(approximating percent DNA methylation at a CpG site) as the out-
come, and MetS (or individual component) and tumor status as
predictors, adjusting for confounders and estimated cell proportions
and batch effects. We will correct for multiple comparisons using
a Bonferroni correction setting α = 1.1 × 10−7, and also use false
discover rate correction for multiple testing. We will construct Man-
hattan plots to present results of our epigenome-wide association
analysis of MetS, and use mixed models to compare methylation of the
top CpG sites by MetS and individual component and tumor status.
Sample Size and Power
With prevalence of MetS ranging from 20% to 40%, on the basis of
prior reports, and setting α at .05, we calculated the minimum
sample size needed to maintain 80% power. On the basis of this
analysis, we set our minimum sample size at 350 per group (700
total) to detect an odds ratio (OR) of at least 1.50 for the association
between MetS and incident breast cancer diagnosis if MetS prev-
alence is at least 30%. On the basis of the reported prevalence of the
least common breast cancer subtype (triple-negative breast cancer
[TNBC]) in Nigeria of 32%39 and observed OR of the association
between MetS and TNBC of 2.40,40 we should have the 112 (32% of
350) women with TNBC needed to detect an OR of 2.0 for the
association between MetS and TNBC subtype with 80% power. We
calculated the minimum sample size required to detect at least
a 10% methylation difference at speciﬁc CpG sites between tumor
and normal tissues, setting power at 80% and α at 10−5 to correct for
multiple comparisons. We chose 10% difference as a conservative
estimate, because prior studies routinely reported two- to three-fold
methylation differences between tumor and normal tissues. Because
tumor and normal tissues are from the same patient, we anticipate
low estimated variance and large tumor-normal differences. On the
basis of this analysis, the study is adequately powered to detect at
least a 10% methylation difference with a sample size ranging from
13 (if SD = 5) to 40 (if SD = 12).
TABLE A1. Power and Sample Size
Index
Reference
Proportion
Odds
Ratio
Actual
Power
No. Per
Group
1 0.2 1.5 0.800 421
2 0.2 2.0 0.800 135
3 0.2 2.5 0.804 75
4 0.3 1.5 0.800 335
5 0.3 2.0 0.803 112
6 0.3 2.5 0.802 63
7 0.4 1.5 0.801 306
8 0.4 2.0 0.801 105
9 0.4 2.5 0.803 61
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